Skip to main content
. 2018 Apr 26;9:452. doi: 10.3389/fphys.2018.00452

Table 1.

Main characteristics of the eligible studies.

Author Year Ethnicity Number of patient Trial design Cancer type Cutoff value of positive Gal-9 Localization of Gal-9 Follow-up (months) Medium (range) Outcomes Model Method Specimen NOS score
Irie 2005 Eastern Asian 84 PC Breast cancer H-score > 80 C 188 DFS Uni IHC PEB 8
Zhang 2012 Eastern Asian 200 RC HCC Score > 2, (0–7) C ≥60 OS Multi IHC PEB 7
Gu 2013 Eastern Asian 147 PC HCC NA C, M, N 24.4(9–43) OS, DFS Multi IHC NA 8
Jiang 2013 Eastern Asian 183 PC Gastric cancer H-score > 200 C 40(3–135) OS Uni IHC PEB 8
Kong 2014 Eastern Asian 197 PC HCC H-score > 100 C 21(12–56) OS Uni IHC PEB 8
Schulkens 2014 Caucasian 87 RC NSCLC ≥median NA ≥60 OS, DFS Uni qRT-PCR Frozen tissue 5
Fu 2015 Eastern Asian 196 RC Urinary tumors H-score ≥ median NA 106(12–120) OS, RFS Multi IHC PEB 7
Grosset 2016 Caucasian 98 RC Breast cancer NA C, N 60 DFS Uni IHC PEB 5
Ohue 2016 Eastern Asian 120 PC NSCLC Score = =3,4,6 C, M NA OS Multi IHC PEB 8
Wang 2016 Eastern Asian 90 PC Colon cancer Score = =2,3,4 C 96 OS Multi IHC PEB 8
Choi 2017 Eastern Asian 619 PC Gastric cancer ≥10% of cells HA 65.7(0–79) OS Multi IHC PEB 8
Liu 2017 Eastern Asian 202 RC Urinary tumors H-score = 58–157 C 60.5 OS, RFS Multi IHC PEB 7
Melief 2017 Caucasian 73 PC Melanoma >Median Z-cores NA Upto 120 OS Multi IFS PEB 8
Sideras 2017 Caucasian 94 RC HCC Score = 1,2,3 (0–3) C NA OS Multi IHC PEB 7

PC, prospective cohort; RC, retrospective cohort; HCC: hepatocellular carcinoma; NSCLC, non-small cell lung cancer; C, cytoplasm; M, cell membrane; N, nucleus; OS, overall survival; DFS, disease-free survival; RFS, recurrence-free survival; Multi, multivariate; Uni, univariate; IHC, immunohistochemistry; IFS, immunofluorescence staining; qRT-PCR, quantitative real-time polymerase chain reaction; PEB, paraffin embedded block; N.A., not available.